Davenport & Co’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Davenport & Co’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,500	Closed	-$5.55K	–	1105
2023 Q1	$5.55K	Sell	1,500 -525	-26%	-$2.42K	﹤0.01%	1037
2022 Q4	$7.7K	Hold	2,025	–	–	﹤0.01%	1001
2022 Q3	$16K	Sell	2,025 -250	-11%	-$4.14K	﹤0.01%	986
2022 Q2	$48K	Hold	2,275	–	–	﹤0.01%	978
2022 Q1	$86K	Sell	2,275 -150	-6%	-$5.19K	﹤0.01%	1038
2021 Q4	$136K	Sell	2,425 -500	-17%	-$33.6K	﹤0.01%	1044
2021 Q3	$211K	Buy	2,925 +75	+3%	+$5.74K	﹤0.01%	965
2021 Q2	$273K	Sell	2,850 -125	-4%	-$13.8K	﹤0.01%	826
2021 Q1	$440K	Hold	2,975	–	–	﹤0.01%	557
2020 Q4	$416K	Buy	+2,975	New	+$482K	﹤0.01%	569

Other funds holding NBSE

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

DCMIC

Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return

CMU

Carnegie Mellon University Pittsburgh, Pennsylvania $64.3M AUM 35.71% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

JAMONY

Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Davenport & Co's NBSE Position: Q2 2023 in Review

Davenport & Co sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2023, closing a stake of 1,500 shares — an estimated $5.55K sold.

Davenport & Co first reported a position in NBSE in Q4 2020 and held it in 10 quarters. The position peaked at $440K in Q1 2021. 27 funds tracked by Wall St. Rank hold NBSE as of Q2 2023.

Davenport & Co reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Davenport & Co sold 1,500 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $5.55K.
Davenport & Co first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q4 2020 and held it in 10 quarters.
Davenport & Co's NeuBase Therapeutics, Inc. Common Stock position peaked at $440K in Q1 2021.
27 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Davenport & Co's 13F filing for Q2 2023, filed 20 Jul 2023.